Trial Profile

A pivotal trial assessing XmAb819 in Clear Cell Renal Cell Carcinoma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XmAb 819 (Primary)
Indications Renal cell carcinoma
Focus Registrational; Therapeutic Use
Sponsors Xencor

Most Recent Events

19 Nov 2025 New trial record
24 Oct 2025 According to a Xencor media release, the company will be able to select a recommended Phase 3 dose during 2026 to support the initiation of first pivotal study in advanced ccRCC during 2027

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com